4.7 Article

The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials

Journal

Publisher

SPRINGER
DOI: 10.1007/s00259-008-0874-2

Keywords

Standardisation; FDG; PET; Multi-centre trials; QC; SUV; Quantification

Ask authors/readers for more resources

Introduction Several studies have shown the usefulness of positron emission tomography (PET) quantification using standardised uptake values (SUV) for diagnosis and staging, prognosis and response monitoring. Many factors affect SUV, such as patient preparation procedures, scan acquisition, image reconstruction and data analysis settings, and the variability in methodology across centres prohibits exchange of SUV data. Therefore, standardisation of 2-[F-18] fluoro-2-deoxy-D-glucose (FDG) PET whole body procedures is required in multi-centre trials. Methods A protocol for standardisation of quantitative FDG whole body PET studies in the Netherlands (NL) was defined. This protocol is based on standardisation of: (1) patient preparation; (2) matching of scan statistics by prescribing dosage as function of patient weight, scan time per bed position, percentage of bed overlap and image acquisition mode (2D or 3D); (3) matching of image resolution by prescribing reconstruction settings for each type of scanner; (4) matching of data analysis procedure by defining volume of interest methods and SUV calculations and; (5) finally, a multi-centre QC procedure is defined using a 20-cm diameter phantom for verification of scanner calibration and the NEMA NU 2 2001 Image Quality phantom for verification of activity concentration recoveries (i.e., verification of image resolution and reconstruction convergence). Discussion This paper describes a protocol for standardization of quantitative FDG whole body multi-centre PET studies. Conclusion The protocol was successfully implemented in the Netherlands and has been approved by the Netherlands Society of Nuclear Medicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Radiology, Nuclear Medicine & Medical Imaging

Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules

Elizabeth J. de Koster, Wyanne A. Noortman, Jacob M. Mostert, Jan Booij, Catherine B. Brouwer, Bart de Keizer, John M. H. de Klerk, Wim J. G. Oyen, Floris H. P. van Velden, Lioe-Fee De Geus-Oei, Dennis Vriens

Summary: The study aimed to evaluate whether quantitative [F-18]FDG-PET/CT assessment and radiomic analysis of [F-18]FDG-positive thyroid nodules could improve the preoperative differentiation of indeterminate thyroid nodules. The results showed that applying distinct SUV cut-offs for non-Hurthle cell and Hurthle cell nodules can optimize the ability to rule out malignancy, while radiomic analysis did not provide additional differentiation for [F-18]FDG-positive nodules.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

[18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial

Elizabeth J. de Koster, Lioe-Fee de Geus-Oei, Adrienne H. Brouwers, Eveline W. C. M. van Dam, Lioe-Ting Dijkhorst-Oei, Adriana C. H. van Engen-van Grunsven, Wilbert B. van den Hout, Tamira K. Klooker, Romana T. Netea-Maier, Marieke Snel, Wim J. G. Oyen, Dennis Vriens

Summary: The study aimed to assess the impact of an [F-18]FDG-PET/CT-driven diagnostic workup on patients with indeterminate thyroid nodules. The results showed that this workup accurately reduced futile surgeries by 40% and should be limited to non-Hurthle cell nodules.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Article Rheumatology

18F-FDG PET-CT in rheumatoid arthritis patients tapering TNFi: reliability, validity and predictive value

Chantal A. M. Bouman, Noortje van Herwaarden, Annelies B. Blanken, Conny J. Van der Laken, Martin Gotthardt, Wim J. G. Oyen, Alfons A. den Broeder, Aatke van der Maas, Cornelia H. van den Ende

Summary: FDG-PET arthritis scoring in RA patients with low disease activity is reliable and has some construct validity, but no predictive values were found for FDG-PET parameters for successful tapering and/or discontinuation of TNFi.

RHEUMATOLOGY (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial

Elizabeth J. de Koster, Dennis Vriens, Maarten O. van Aken, Lioe-Ting Dijkhorst-Oei, Wim J. G. Oyen, Robin P. Peeters, Abbey Schepers, Lioe-Fee De Geus-Oei, Wilbert B. van den Hout

Summary: This study evaluates the cost-effectiveness of an [F-18]FDG-PET/CT-driven diagnostic workup compared to diagnostic surgery for thyroid nodules with Bethesda III/IV cytology. The results show that [F-18]FDG-PET/CT avoids unnecessary diagnostic surgeries and reduces costs while maintaining quality of life.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Perspectives on translational molecular imaging and therapy: an overview of key questions to be addressed

Fijs W. B. van Leeuwen, Margret Schottelius, Felix M. Mottaghy, Fabien Hyafil, Mark Lubberink, Gabriela Kramer-Marek, Wim J. G. Oyen

EJNMMI RESEARCH (2022)

Review Oncology

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer

Wietske I. Luining, Matthijs C. F. Cysouw, Dennie Meijer, N. Harry Hendrikse, Ronald Boellaard, Andre N. Vis, Daniela E. Oprea-Lager

Summary: Imaging plays a crucial role in the accurate staging of prostate cancer, and targeting the prostate-specific membrane antigen (PSMA) protein has become of great clinical value. PSMA-based imaging techniques have shown superior detection rates compared to previous methods, and PSMA has also become a target for delivering radionuclide therapy. This review summarizes recent developments in nuclear medicine related to PSMA in prostate cancer diagnostics and targeted radionuclide therapy, highlighting the potential benefits of PSMA-positron emission tomography (PET) imaging and PSMA-based radioligand therapy in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

CANCERS (2022)

Article Oncology

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy

Maarten J. van der Doelen, Irma M. Oving, Dirk N. J. Wyndaele, Jean-Paul van Basten, Frederiek Terheggen, Addy C. M. van de Luijtgaarden, Wim J. G. Oyen, W. Dick van Schelven, Franchette van den Berkmortel, Niven Mehra, Marcel J. R. Janssen, Judith B. Prins, Winald R. Gerritsen, Jose A. E. Custers, Inge M. van Oort

Summary: This study evaluated the health-related quality of life, psychological distress, and fatigue in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223. The study found that patients who discontinued radium-223 therapy had worse HR-QoL, psychological distress, and fatigue at baseline and more frequent deterioration over time compared to patients who completed therapy.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Article Endocrinology & Metabolism

Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules

Elizabeth J. de Koster, Olga Husson, Eveline W. C. M. van Dam, G. Sophie Mijnhout, Romana T. Netea-Maier, Wim J. G. Oyen, Marieke Snel, Lioe-Fee de Geus-Oei, Dennis Vriens

Summary: The study examined HRQoL in patients undergoing FDG-PET/CT for an indeterminate thyroid nodule, finding that active surveillance following a negative FDG result resulted in stable HRQoL scores over a year. Patients with benign histopathology who underwent diagnostic surgery had more cognitive impairment and physical problems, but improved goitre symptoms and anxiety. Anxiety also decreased in patients with malignant histopathology.

ENDOCRINE CONNECTIONS (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

[18F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules

Elizabeth J. de Koster, Adriana C. H. van Engen-van Grunsven, Johan Bussink, Cathelijne Frielink, Lioe-Fee de Geus-Oei, Benno Kusters, Hans Peters, Wim J. G. Oyen, Dennis Vriens

Summary: This study explored the association between [F-18]FDG uptake and the quantitative expression of immunohistochemical markers related to glucose metabolism, hypoxia, and cell proliferation in benign and malignant thyroid nodules of indeterminate cytology. The results showed that the expression of GLUT1, HK2, and MCT4 increased in [F-18]FDG-positive benign nodules and thyroid carcinomas as compared to [F-18]FDG-negative benign nodules, and VEGF expression was higher in thyroid carcinomas.

MOLECULAR IMAGING AND BIOLOGY (2023)

Letter Radiology, Nuclear Medicine & Medical Imaging

Preoperative stratification of cytologically indeterminate thyroid nodules by [18F]FDG-PET: can Orpheus bring back Eurydice?

Dennis Vriens, Elizabeth J. de Koster, Lioe-Fee de Geus-Oei, Wim J. G. Oyen, EfFECTS trial consortium

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Article Medicine, General & Internal

[18F]FDG PET/CT in Large Vessel Vasculitis: The Impact of Expertise and Confounders on Image Analysis

Lidija Antunovic, Alessia Artesani, Michael Coniglio, Wim J. G. Oyen, Michele Ciccarelli, Carlo Selmi, Arturo Chiti, Martina Sollini

Summary: This study evaluated the diagnostic accuracy of [F-18]-fluorodeoxyglucose ([F-18]FDG) PET/CT in large vessel vasculitis (LVV) and found that an experienced reader had higher accuracy compared to a less experienced one. The expert reader performed better in patients with normal BMI, normal glycemia, younger age, and no ongoing therapy. The use of semi-quantitative parameters did not improve the diagnostic performance of the readers.

DIAGNOSTICS (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial

H. Adams, E. M. W. van de Garde, D. J. Vugts, J. C. Grutters, Wim. J. G. Oyen, R. G. Keijsers

Summary: This study investigates the use of imaging CD20-positive cells in predicting the response to anti-CD20 treatment for immune-mediated interstitial lung disease. PET/CT imaging was performed on 21 patients, and it was found that the uptake of [89Zr]-rituximab in the lungs correlated with changes in pulmonary function test results and treatment outcomes. Patients with a higher uptake of [89Zr]-rituximab had better response to treatment. Therefore, [89Zr]-rituximab PET imaging may serve as a potential predictive biomarker for anti-CD20 therapy.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Article Oncology

A clinically applicable molecular classification of oncocytic cell thyroid nodules

Elizabeth J. de Koster, Willem E. Corver, Lioe-Fee de Geus-Oei, Wim J. G. Oyen, Dina Ruano, Abbey Schepers, Marieke Snel, Tom van Wezel, Dennis Vriens, Hans Morreau

Summary: This study described the patterns of copy number alterations (CNA) in benign and malignant oncocytic cell thyroid neoplasms (OCN) using a next-generation sequencing (NGS) panel. The study found that the CNA patterns differed between benign and malignant cases, and suggested the application of CNA-LOH analysis using the NGS panel in the molecular diagnostics of OCN.

ENDOCRINE-RELATED CANCER (2023)

Article Oncology

EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy

Stefano Fanti, Alberto Briganti, Louise Emmett, Karim Fizazi, Silke Gillessen, Karolien Goffin, Boris A. Hadaschik, Ken Herrmann, Jolanta Kunikowska, Tobias Maurer, Steven MacLennan, Nicolas Mottet, Declan G. Murphy, Daniela E. Oprea-Lager, Joe M. O'Sullivan, Wim J. G. Oyen, Olivier Rouviere, Oliver Sartor, Arnulf Stenzl, Hendrik Van Poppel, Jochen Walz, Wim Witjes, Anders Bjartell

Summary: The use and potential of PSMA PET/CT in prostate cancer treatment and management were assessed and achieved consensus among a panel of experts, particularly in utilizing PSMA PET/CT for patient selection and guiding [177Lu]Lu-PSMA therapy.

EUROPEAN UROLOGY ONCOLOGY (2022)

Review Oncology

Toward Improved Outcomes for Patients With Lung Cancer Globally: The Essential Role of Radiology and Nuclear Medicine

Miriam N. Mikhail Lette, Diana Paez, Lawrence N. Shulman, Mathias Guckenberger, Jean-Yves Douillard, Wim J. G. Oyen, Francesco Giammarile, Venkatesh Rangarajan, Michelle Ginsberg, Olivier Pellet, Zhongxing Liao, May Abdel Wahab

Summary: This paper emphasizes the importance of improving medical imaging and nuclear medicine infrastructure globally to achieve better outcomes for lung cancer patients. It highlights the significant role of imaging findings in treatment selection and patient outcomes, and discusses the current gaps in diagnostics and therapies. The paper also emphasizes the high burden of lung cancer in low- and middle-income countries and the need for strategic planning to improve population-based outcomes.

JCO GLOBAL ONCOLOGY (2022)

No Data Available